M
Masao Iwata
Researcher at Eisai
Publications - 28
Citations - 1626
Masao Iwata is an academic researcher from Eisai. The author has contributed to research in topics: Cancer & In vivo. The author has an hindex of 11, co-authored 28 publications receiving 1372 citations.
Papers
More filters
Journal ArticleDOI
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Yoshihiko Kotake,Koji Sagane,Takashi Owa,Yuko Mimori-Kiyosue,Hajime Shimizu,Mai Uesugi,Yasushi Ishihama,Yasushi Ishihama,Masao Iwata,Yoshiharu Mizui +9 more
TL;DR: The results demonstrate that the SF3b complex is a pharmacologically relevant protein target of pladienolide and suggest that this splicing factor is a potential antitumor drug target.
Journal ArticleDOI
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama,Junji Matsui,Kotaro Kodama,Naoko Hata-Sugi,Takayuki Kimura,Kiyoshi Okamoto,Yukinori Minoshima,Masao Iwata,Yasuhiro Funahashi +8 more
TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Journal ArticleDOI
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Kiyoshi Okamoto,Kotaro Kodama,Kazuma Takase,Naoko Hata Sugi,Yuji Yamamoto,Masao Iwata,Akihiko Tsuruoka +6 more
TL;DR: It is demonstrated that lenvatinib can exert antitumor activity againstRET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.
Journal ArticleDOI
Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107 : III. In Vitro and In Vivo Antitumor Activities
Yoshiharu Mizui,Takashi Sakai,Masao Iwata,Tosiiimitsu Uenaka,Kiyoshi Okamoto,Hajime Shimizu,Takao Yamori,Kentaro Yoshimatsu,Makoto Asada +8 more
TL;DR: Seven novel 12-membered macrolides from Streptomyces platensis Mer-11107 are discovered, with pladienolide B the most potently inhibiting hypoxia induced-VEGF expression and proliferation of the U251 cancer cell line, and appear to have major potential for use in cancer treatment.
Journal ArticleDOI
Biological validation that SF3b is a target of the antitumor macrolide pladienolide
Akira Yokoi,Yoshihiko Kotake,Kentaro Takahashi,Tadashi Kadowaki,Yoshiko Matsumoto,Yukinori Minoshima,Naoko Hata Sugi,Koji Sagane,Makoto Hamaguchi,Masao Iwata,Yoshiharu Mizui +10 more
TL;DR: It is shown that pladienolide exerts its potent activity by targeting SF3b and also suggest that inhibition of SF3B is a promising drug target for anticancer therapy.